Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer – A multicenter observational analysis
Nikolaj Frost(Humboldt-Universität zu Berlin), Jens Kollmeier(Helios Klinikum Emil von Behring), Martin Witzenrath(Humboldt-Universität zu Berlin), Carolin Senger(Freie Universität Berlin), Dominik Paul Modest(Berliner Hochschule für Technik), Matthias Raspe(Charité - Universitätsmedizin Berlin), Moritz Hilbrandt(Humboldt-Universität zu Berlin), S Kurz(Evangelische Lungenklinik Berlin), Torsten Blum(MSB Medical School Berlin), Kristina Unger(Humboldt-Universität zu Berlin), Myriam Koch(University Hospital Regensburg), Elisabeth Olive(Evangelische Lungenklinik Berlin), H Lüders(Evangelische Lungenklinik Berlin), Daniel Misch(Helios Klinikum Emil von Behring), Torsten Bauer(Helios Klinikum Emil von Behring), Christian Grohé(DRK Kliniken Berlin), Dirk Böhmer(Humboldt-Universität zu Berlin)
Cited by 18
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
|European Journal of Cancer|2016|533